Please login to the form below

Not currently logged in
Email:
Password:

immunotherapies

This page shows the latest immunotherapies news and features for those working in and with pharma, biotech and healthcare.

European Commission approves Opdivo plus Cambometyx for advanced kidney cancer

European Commission approves Opdivo plus Cambometyx for advanced kidney cancer

Today's milestone builds on our heritage of developing and delivering novel treatments for patients with advanced renal cell carcinoma, first with the only dual immunotherapy option, Opdivo plus Yervoy, and ... now with a new immunotherapy and tyrosine

Latest news

More from news
Approximately 99 fully matching, plus 531 partially matching documents found.

Latest Intelligence

  • Sourcing R&D innovation: why pharma companies need to evolve their business models Sourcing R&D innovation: why pharma companies need to evolve their business models

    The global pharmaceutical and biotechnology industries have achieved many significant milestones in innovative research and drug development in the past decade – including the broad adoption of immunotherapies and the introduction of

  • Switzerland: a life sciences hub Switzerland: a life sciences hub

    For example, over the last five years, Lundbeck acquired Prexton Therapeutics, Agilent acquired Genohm and Boehringer Ingelheim acquired Amal Therapeutics, focused on cancer immunotherapy and therapeutic cancer vaccines.

  • Cortellis Drugs to Watch in 2020 report Cortellis Drugs to Watch in 2020 report

    Liso-cel (lisocabtagene maraleucel, JCAR-017) is an immunotherapy comprised of autologous T cells genetically modified (via lentiviral vector) to express an anti-CD19 chimeric antigen receptor (CAR).

  • Pharma funding and M&A in 2020 Pharma funding and M&A in 2020

    Indeed, 2019 was notable for Bristol-Myers Squibb’s acquisition of Celgene (which at a stroke bolstered its immunotherapy and oncology departments), as well as AbbVie’s acquisition of Allergan for ... Indeed, a key theme of the deals I have mentioned

  • It started with a miss It started with a miss

    However, we’re now moving into areas like immunotherapy and are on the edge of amazing innovations that will deliver great outcomes for patients.

More from intelligence
Approximately 5 fully matching, plus 57 partially matching documents found.

Latest appointments

More from appointments
Approximately 2 fully matching, plus 47 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 11 fully matching, plus 17 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
ROAD

ROAD is a digital PR and communications consultancy specialising in promoting the innovators that shape our future health and wellbeing....

Latest intelligence

Are you ready for the digital health revolution?
In this edition of Delta magazine, we explore how rapid digitalization has transformed the care pathway and reveal how life science companies can succeed in the digital age....
#DemandDiversity: Can new medical publication guidelines help fix diversity in clinical trials?
Over the last 8 months, JAMA have been working on a new set of guidelines for research papers looking to publish with them, which is summarised in their latest editorial...
DATA shutterstock_1818502577-640.jpg
Empowering patients empowers results
Patient-centricity is key when it comes to creating a more flexible, efficient and modern process for clinical trials...

Infographics